Quantbot Technologies LP Invests $1.70 Million in Omada Health, Inc. $OMDA

Key Points

• Quantbot Technologies LP acquired 77,200 Omada Health shares in the second quarter, investing approximately $1.70 million for a 0.13% stake. Other major institutions, including BlackRock and Perceptive Advisors, also established positions.
• Omada Health reported quarterly EPS of $0.08, beating estimates by $0.10, while revenue reached $87.83 million versus the $80.93 million consensus forecast.
• Analysts maintain a generally bullish outlook, with an average “Moderate Buy” rating and a $26.50 price target. However, insiders sold 254,726 shares worth approximately $5.37 million over the past 90 days.

Quantbot Technologies LP purchased a new stake in Omada Health, Inc. (NASDAQ:OMDA - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 77,200 shares of the company's stock, valued at approximately $1,695,000. Quantbot Technologies LP owned 0.13% of Omada Health as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Perceptive Advisors LLC purchased a new stake in Omada Health during the second quarter valued at about $44,402,000. Millennium Management LLC increased its position in shares of Omada Health by 1,195.0% in the fourth quarter. Millennium Management LLC now owns 2,272,168 shares of the company's stock worth $35,855,000 after acquiring an additional 2,096,705 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Omada Health during the second quarter valued at approximately $48,775,000. Loomis Sayles & Co. L P raised its holdings in shares of Omada Health by 23.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,855,721 shares of the company's stock valued at $29,283,000 after acquiring an additional 346,588 shares during the period. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Omada Health in the 4th quarter valued at approximately $16,948,000.

Insider Activity at Omada Health

In other news, CFO Steven L. Cook sold 33,000 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $19.89, for a total transaction of $656,370.00. Following the transaction, the chief financial officer owned 133,359 shares in the company, valued at $2,652,510.51. This represents a 19.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Sean P. Duffy sold 25,886 shares of the firm's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $22.68, for a total transaction of $587,094.48. Following the transaction, the chief executive officer owned 411,861 shares in the company, valued at $9,341,007.48. This represents a 5.91% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 254,726 shares of company stock worth $5,370,496. Insiders own 6.38% of the company's stock.

Omada Health Price Performance

Shares of OMDA stock opened at $24.08 on Tuesday. Omada Health, Inc. has a fifty-two week low of $10.28 and a fifty-two week high of $26.92. The stock's 50-day moving average is $21.75 and its two-hundred day moving average is $16.87. The firm has a market cap of $1.47 billion, a P/E ratio of 481.60 and a beta of 1.73.

Omada Health (NASDAQ:OMDA - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.10. The business had revenue of $87.83 million during the quarter, compared to analyst estimates of $80.93 million. Omada Health had a return on equity of 2.60% and a net margin of 1.39%. As a group, research analysts expect that Omada Health, Inc. will post 0.09 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on OMDA shares. JPMorgan Chase & Co. raised their price objective on shares of Omada Health from $26.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, August 14th. Citizens Jmp boosted their target price on shares of Omada Health from $27.00 to $32.00 and gave the company a "market outperform" rating in a research note on Friday, August 14th. Robert W. Baird increased their target price on Omada Health from $15.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, August 12th. BMO Capital Markets reaffirmed an "outperform" rating and issued a $24.00 target price on shares of Omada Health in a research report on Friday, August 7th. Finally, Citigroup reiterated an "outperform" rating on shares of Omada Health in a report on Friday, August 14th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $26.50.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company's platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source